乳腺影像中碘对比剂给药相关风险:要点与现有证据概述——一篇叙述性综述
该叙述性综述检索2017年1月至2025年2月的指南及乳腺对比增强成像研究,纳入9部国际指南。碘对比剂超敏反应发生率为0.3%-0.7%,急性肾损伤至少5%、慢性肾病患者可升至30%;建议用问卷筛查慢性肾病风险,乳腺影像风险与增强CT相似但更低。
要点
- 碘对比剂超敏反应发生率0.3%-0.7%,轻度反应后应观察至少30分钟。
- 急性肾损伤至少5%,慢性肾病患者可升至30%。
- 当前指南建议用患者问卷针对性筛查慢性肾病风险。
核心结论
- 乳腺影像中碘对比剂风险与增强CT相似,但因门诊人群风险较低且非紧急,发生频率倾向于更低。
- 超敏反应和急性肾损伤均不常见,高风险患者可通过问卷识别。
研究设计与样本
- 叙述性综述,检索PubMed和Embase,纳入2017年1月至2025年2月间关于碘对比剂安全使用的指南及乳腺对比增强成像研究。
- 共纳入9部来自国际医学和放射学协会的指南,排除亚专科、动脉内给药及过时版本指南。
诊断标准与关键数值
- 碘对比剂超敏反应发生率为0.3%-0.7%,可能严重,部分需治疗如H1抗组胺药或肌内肾上腺素。
- 急性肾损伤发生率至少5%,慢性肾病患者可升至30%。
- 当前指南建议用患者问卷针对性筛查慢性肾病风险,适用于乳腺影像。
临床应用与阅片要点
- 任何发生轻度超敏反应的患者给药后应观察至少30分钟。
- 乳腺影像中可用患者问卷针对性筛查慢性肾病风险。
局限性
- 多数证据来自增强CT研究,但所用非离子低渗碘对比剂与乳腺对比增强成像相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Contrast-enhanced mammography (CEM) and dedicated breast computed tomography (dBCT) are advanced breast imaging techniques that utilize iodine-based contrast media (ICM) to improve the visualization of tumor vascularity. This review explores key challenges related to ICM use in these imaging modalities, focusing on hypersensitivity reactions (HR), acute kidney injury (AKI), and risk screening.
METHODS: A narrative review was conducted to summarize the available evidence based on guidelines, recommended questionnaires, and relevant recent research. A literature search using PubMed and Embase identified guidelines on the safe use of ICM from January 2017 to February 2025, along with studies on CEM and dBCT. Keywords included (synonyms of) "iodine-based contrast media," "hypersensitivity reactions to ICM," "kidney function tests," "contrast-associated acute kidney injury," "contrast-induced acute kidney injury," and "contrast-enhanced mammography," "dedicated breast CT." Guidelines related to subspecialties, intra-arterial contrast administration, and outdated versions were excluded.
RESULTS: Nine guidelines from international medical and radiological associations were included. While the majority of evidence comes from studies on contrast-enhanced computed tomography (CECT), the findings are applicable to CEM and dBCT as they use similar non-ionic low-osmolar ICM. HR with ICM is rare (0.3 %-0.7 %) but can be severe, with some requiring treatment (e.g., H1-antihistamines or intramuscular adrenaline). Any patient experiencing a mild HR should be observed for at least 30 min after administration. AKI occurs in at least 5 % of cases, which may rise to 30 % in patients with chronic kidney disease (CKD). Current guidelines suggest targeted testing for CKD risk using patient questionnaires, which is applicable to breast imaging, given the low prevalence of advanced CKD in this population.
CONCLUSION: ICM risks in breast imaging are similar to CECT but tend to occur less often due to the lower-risk, non-urgent outpatient population. Both HR and AKI are infrequent, and at-risk patients can be identified through questionnaires.
引用
- van Nijnatten TJA, Meltem E, van der Molen AJ, et al. Contrast-associated risks of iodine-based contrast media administration in breast imaging: Tips and overview of existing evidence - A narrative review. Eur J Radiol. 2025. PMID: 41138316. doi:10.1016/j.ejrad.2025.112481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。